Ameriprise Financial Inc. Has $46.92 Million Position in The Chemours Company $CC

Key Points

• Ameriprise Financial Inc. has reduced its stake in The Chemours Company by 20.7%, now holding approximately 2.32% of the company valued at $46.92 million after selling 905,160 shares in the first quarter.
• Analysts have mixed views on Chemours, with Morgan Stanley lowering its price target from $22 to $15, while Mizuho raised theirs from $13 to $16, reflecting a general consensus target price of $17.38.
• The Chemours Company reported earnings of $0.58 per share in its last quarterly results, exceeding expectations, and announced a quarterly dividend of $0.0875 per share, indicating ongoing financial engagement despite a negative net margin.

Ameriprise Financial Inc. trimmed its stake in The Chemours Company (NYSE:CC - Free Report) by 20.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,468,012 shares of the specialty chemicals company's stock after selling 905,160 shares during the period. Ameriprise Financial Inc. owned about 2.32% of Chemours worth $46,921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Chemours in the 1st quarter worth $822,000. Principal Financial Group Inc. grew its position in Chemours by 116.3% in the 1st quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock worth $10,041,000 after purchasing an additional 399,097 shares during the last quarter. Janney Montgomery Scott LLC grew its position in Chemours by 22.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 31,886 shares of the specialty chemicals company's stock worth $431,000 after purchasing an additional 5,843 shares during the last quarter. GAMMA Investing LLC grew its position in Chemours by 1,115.2% in the 1st quarter. GAMMA Investing LLC now owns 18,617 shares of the specialty chemicals company's stock worth $252,000 after purchasing an additional 17,085 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in Chemours by 8.7% in the 1st quarter. Bessemer Group Inc. now owns 38,554 shares of the specialty chemicals company's stock worth $522,000 after purchasing an additional 3,081 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Chemours

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at $2,310,044.76. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Damian Gumpel purchased 7,822 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $9.95 per share, with a total value of $77,828.90. Following the transaction, the insider owned 131,701 shares in the company, valued at $1,310,424.95. This trade represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 25,290 shares of company stock valued at $250,437. 0.34% of the stock is owned by corporate insiders.

Chemours Price Performance

Shares of NYSE CC traded up $0.31 during trading on Friday, reaching $15.38. The company had a trading volume of 2,896,747 shares, compared to its average volume of 4,114,616. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $22.38. The stock has a market cap of $2.30 billion, a PE ratio of -5.49 and a beta of 1.61. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The business's 50 day moving average price is $13.33 and its 200-day moving average price is $12.78.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the firm posted $0.38 earnings per share. The company's revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's payout ratio is currently -12.50%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group reduced their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Morgan Stanley reduced their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Finally, Mizuho raised their price objective on shares of Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.38.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.